MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Galés, C.
Right arrow Articles by Silvente-Poirot, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Galés, C.
Right arrow Articles by Silvente-Poirot, S.

Vol. 63, Issue 5, 973-982, May 2003

Identification of Tyrosine 189 and Asparagine 358 of the Cholecystokinin 2 Receptor in Direct Interaction with the Crucial C-Terminal Amide of Cholecystokinin by Molecular Modeling, Site-Directed Mutagenesis, and Structure/Affinity Studies

Céline Galés, Marc Poirot, Julien Taillefer, Bernard Maigret, Jean Martinez, Luis Moroder, Chantal Escrieut, Lucien Pradayrol, Daniel Fourmy, and Sandrine Silvente-Poirot

Institut National de la Santé et de la Recherche Médicale (INSERM) U 531, Institut Louis Bugnard, CHU Rangueil, Toulouse, France (C.G., J.T., C.E., L.P., D.F.); INSERM U 563, Département Innovation Thérapeutique et Oncologie Moléculaire, Institut Claudius Regaud, Toulouse, France (M.P.); Laboratoire de Chimie Théorique, Université de Nancy, Vandoeuvre, Nancy, France (B.M.); Centre National de la Recherche Scientifique-Unité de Recherche Associée 1845, Faculté de Pharmacie, Montpellier, France (J.M.); and Max Planck Institute für Biochemie, Martinsried, Germany (L.M.).

The cholecystokinin (CCK) receptors CCK1R and CCK2R exert important central and peripheral functions by binding the neuropeptide cholecystokinin. Because these receptors are potential therapeutic targets, great interest has been devoted to the identification of efficient ligands that selectively activate or inhibit these receptors. A complete mapping of the CCK binding site in these receptors would help to design new CCK ligands and to optimize their properties. In this view, a molecular model of the CCK2R occupied by CCK was built to identify CCK2R residues that interact with CCK functional groups. No such study has yet been reported for the CCK2R. Docking of CCK in the receptor was performed by taking into account our previous mutagenesis data and by using, as constraint, the direct interaction that we demonstrated between His207 in the CCK2R and Asp8 of CCK (Mol Pharmacol 54:364-371, 1998; J Biol Chem 274:23191-23197, 1999). Two residues that had not been revealed in our previous mutagenesis studies, Tyr189 (Y4.60) and Asn358 (N6.55), were identified in interaction via hydrogen bonds with the C-terminal amide of CCK, a crucial functional group of the peptide. Mutagenesis of Tyr189 (Y4.60) and Asn358 (N6.55) as well as structure-affinity studies with modified CCK analogs validated these interactions and the involvement of both residues in the CCK binding site. These results indicate that the present molecular model is an important tool to identify direct contact points between CCK and the CCK2R and to rapidly progress in mapping of the CCK2R binding site. Moreover, comparison of the present CCK2R.CCK molecular model with that of CCK1R.CCK, which we have previously published and validated, clearly argues that the positioning of CCK in these receptors is different.


Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
M. Foucaud, E. Marco, C. Escrieut, C. Low, B. Kalindjian, and D. Fourmy
Linking Non-peptide Ligand Binding Mode to Activity at the Human Cholecystokinin-2 Receptor
J. Biol. Chem., December 19, 2008; 283(51): 35860 - 35868.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. Marco, M. Foucaud, I. Langer, C. Escrieut, I. G. Tikhonova, and D. Fourmy
Mechanism of Activation of a G Protein-coupled Receptor, the Human Cholecystokinin-2 Receptor
J. Biol. Chem., September 28, 2007; 282(39): 28779 - 28790.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. R. Paillasse, C. Deraeve, P. de Medina, L. Mhamdi, G. Favre, M. Poirot, and S. Silvente-Poirot
Insights into the Cholecystokinin 2 Receptor Binding Site and Processes of Activation
Mol. Pharmacol., December 1, 2006; 70(6): 1935 - 1945.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
M. Dufresne, C. Seva, and D. Fourmy
Cholecystokinin and gastrin receptors.
Physiol Rev, July 1, 2006; 86(3): 805 - 847.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. Foucaud, I. G. Tikhonova, I. Langer, C. Escrieut, M. Dufresne, C. Seva, B. Maigret, and D. Fourmy
Partial Agonism, Neutral Antagonism, and Inverse Agonism at the Human Wild-Type and Constitutively Active Cholecystokinin-2 Receptors
Mol. Pharmacol., March 1, 2006; 69(3): 680 - 690.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
I. Langer, I. G. Tikhonova, M.-A. Travers, E. Archer-Lahlou, C. Escrieut, B. Maigret, and D. Fourmy
Evidence That Interspecies Polymorphism in the Human and Rat Cholecystokinin Receptor-2 Affects Structure of the Binding Site for the Endogenous Agonist Cholecystokinin
J. Biol. Chem., June 10, 2005; 280(23): 22198 - 22204.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics